2007
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial
Sternberg C, Petrylak D, Witjes F, Ferrero J, Eymard J, Falcon S, Chatta K, Vaughn D, Berry W, Sartor O. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Journal Of Clinical Oncology 2007, 25: 5019-5019. DOI: 10.1200/jco.2007.25.18_suppl.5019.Peer-Reviewed Original ResearchProgression-free survivalIndependent review committeePain progressionPrior docetaxelPrior chemotherapyRadiologic progressionPain responseSide effectsNon-hematologic side effectsRandomized phase III trialGrade 4 neutropeniaGrade 4 thrombocytopeniaObjective tumor responseDouble-blind studyFrequent side effectsPhase III trialsTreatment of patientsSignificant clinical benefitHRPC patientsSPARC trialTreat basisIII trialsPlacebo armPrimary endpointPSA response
2006
Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone
Sleep D, Nelson J, Petrylak D, Isaacson J, Carducci M. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. Journal Of Clinical Oncology 2006, 24: 4630-4630. DOI: 10.1200/jco.2006.24.18_suppl.4630.Peer-Reviewed Original ResearchHormone-refractory prostate cancerDisease progressionHRPC patientsBone metastasesProstate cancer metastaticKaplan-Meier methodDelays disease progressionEffects of endothelinDisease progression eventsCox proportional hazardsProgression of morbidityBone painCancer metastaticRadiographic progressionProlong survivalClinical benefitClinical progressionSelective endothelinClinical eventsReceptor antagonistMultinational trialProstate cancerClinical meansAtrasentanNew therapiesA phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results
Oh W, Manola J, Ross R, Berkowitz A, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. Journal Of Clinical Oncology 2006, 24: 14533-14533. DOI: 10.1200/jco.2006.24.18_suppl.14533.Peer-Reviewed Original ResearchHormone refractory prostate cancerPhase II trialDocetaxel chemotherapyHormone refractory prostate cancer patientsPhase II trial of docetaxelMedian time to progressionDocetaxel-based therapyTrial of docetaxelRefractory prostate cancerTime to progressionDocetaxel-based chemotherapyEfficacy of docetaxel chemotherapyStaging of patientsBaseline performance statusCarboplatin AUCHRPC patientsMedian PSAPSA declineRECIST criteriaMedian survivalNeuroendocrine differentiationII trialMedian agePerformance statusProstate cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply